Ageing of the extracellular matrix (ECM), the protein matrix that surrounds and penetrates the tissues and binds the body together, contributes significantly to functional aging of tissues. ECM proteins become increasingly cross-linked with age, and this cross-linking is probably important in the decline of the ECM's function. In this paper I review the role of EGGL, a cross-link formed by transglutaminase enzymes, and particularly the widely expressed isozyme TG2, in the aging ECM. There is little direct data on EGGL accumulation with age, and no direct evidence of a role of EGGL in the aging of the ECM outwith pathology. However, several lines of circumstantial evidence suggest that EGGL accumulates with age, and its association with pathology suggests that this might reflect degradation of ECM function. TG activity increases with age in many circumstances, ECM protein turnover is such that some EGGL made by TG is likely to remain in place for years if not decades in healthy tissue, and both EGGL and TG levels are enhanced by agerelated diseases. If further research shows EGGL does accumulate with age, removing it could be of therapeutic benefit. I review blockade of TG and active removal of EGGL as therapeutic strategies, and conclude that both have promise. EGGL removal may have benefit for acute fibrotic diseases such as tendinopathy, and for treating generalized decline in ECM function with old age. Extracellular TG2 and EGGL are therefore therapeutic targets both for specific and more generalized diseases of aging.
Tissue cross-links and aging: transglutaminase's role?
It is a truism that we become less flexible as we age. This is literally true of many tissues, which become more mechanically rigid and less amenable to tissue remodeling with age. Loss of flexibility is due at least in part to increased cross-linking of the extracellular protein in the tissue, converting a flexible network of molecules into a rigid mesh. Stiffness increases have been recorded in lung [1] , major arteries [2] [3] [4] , bone [5] [6] [7] , muscle [8, 9] , tendon [10] and lens of the eye [11, 12] among other tissues. In a range of diseases, changes in the mechanical properties of the ECM have been linked to cellular processes as well as mechanical changes in tissue (reviewed in TG2 in aging [13] ). In many of these studies, degradation of mechanical properties has been linked directly to chemical cross-linking of extracellular protein.
Extracellular proteins are chemically cross-linked by several mechanisms in vivo, any of which could contribute to age-related matrix stiffening. Lysyl oxidase (LO) converts the side-chains of lysines in collagen and elastin to aldehyde-containing groups, which can then react with lysines, arginines and histidines in other protein chains to form complex cross-links. The pattern of crosslinks changes with age, but also with fibrosis and tissue scarring [14] : increase in LO cross-links with age could therefore be due to development of chronic fibrotic and inflammatory disease rather than endogenous trends in protein chemistry [15, 16] .
Protein glycation is known to cross-link proteins in vivo, and causes degradation of tissue function [3, 17] . Reducing sugars react non-enzymatically with lysine and arginine side-chains in protein forming complex products, which can then undergo oxidation and react with other basic side-chains on other proteins, forming cross-links. The process does not involve any enzymes, and hence is not under biological control (except to the extent that sugar levels and temperature are controlled). The end products of glycation -called Advanced Glycation Endproducts (AGEs) -are stable under physiological conditions, and so accumulate in long-lived proteins.
Transglutaminases (TGs) are a group of enzymes that catalyze the formation of a peptide bond between the side-chains of glutamine and lysine residues. They are widely expressed, known to be related to disease, and could in principle contribute to the loss of mechanical properties of tissues with age. TGs cross-link proteins inside and outside cells, and so could be a significant contributor to ECM cross-linking and stiffness in health, disease and old age. There have been many reviews of the role of TGs in specific disease states, and I will not repeat these here, nor the extensive literature on the complex mechanisms of TG action: reviews of these studies are cited below. In this review I ask a more specific question. Are extracellular TG cross-links a potential target for blocking or reversing the increased cross-linking of the ECM that occurs with age, and which is likely to be associated with the general increase in morbidity with age? Specifically, do TG crosslinks increase with age, and if they do, is this because TG cross-links 1. inherently increase with the aging of tissue, independent of specific disease 2. increase with aging as a result of low levels of pathology that generally increase with age, without overt or florid disease 3. increase as a consequence of specific episodes of diseases (acute or chronic) that emplace cross-links in long-lived proteins
If TG cross-links do increase with age we are also interested in whether this results in significant changes in ECM function. This paper will start by reviewing the transglutaminases, and specifically tissue transglutaminase, TG2, which is the most ubiquitously expressed of the TG enzyme family. I will then review the meager evidence that TG crosslinks increase with age, before discussing the much larger body of evidence linking TGs with disease. I will then discuss whether TG enzyme activity or TG crosslinks could be good therapeutic targets for the age-related increase in general incapacity and morbidity. I conclude that there is some evidence that an EGGL-breaker could be an attractive new TG2 in aging therapeutic option for tendinopathies, in future may be valuable for treating chronic cardiovascular and kidney disease, and may also provide a route to reversing some of the general ECM crosslinking that accumulates with ageing. However the basic biology should be made more robust before substantial investment is made.
Transglutaminases
The Transglutaminases are a family of enzymes that catalyze the formation of isopeptide bonds between γ-carboxamide groups of glutamine residues and either the ε-amino group of lysine residues (of other protein molecules) or primary amines (reviewed in [18] [19] [20] [21] ). The transglutaminase family in man has eight catalytically active members including the blood clotting enzyme Factor-XIIIA, and one homologous protein without transglutaminase activity [18, 20] .
Transglutaminases can catalyze the direct cross-linking of proteins via a lysine-glutamine isopeptide bond, or indirectly via a polyamine ( Figure 1 ). Transglutaminases only cross-link specific proteins, and vary in their ability to link glutamines to primary amines or to hydrolyze glutamine (reactions 2 and 3 in Figure 1 ). Table 1 summarizes the relevant properties of the known, catalytically active human transglutaminases. In this review I focus on TG2, which is widely expressed and present in the ECM, and so could cause some of the ECM cross-linking that accumulates with age.
Transglutaminase 2 (TG2)
TG2 is a multifunctional protein involved in processes inside and outside the cell. TG2 (also sometimes abbreviated as TGM2) has also been known as Tissue transglutaminase (tTG), transglutaminase C (TG-C), and Gh. TG2 acts as a transglutaminase, a protein kinase [22] , a disulfide isomerase [23] , a G-protein GTPase in selected G-protein-coupled receptors [24] , and interacts directly with fibronectin and integrin, thus mediating cell:ECM interactions (reviewed in [19, [25] [26] [27] ). The TG2 protein is expressed ubiquitously and abundantly, although, as discussed below, transglutaminase enzyme activity is much more restricted. TG2 is found in the cell nucleus, in the cytosol, it can be embedded in the membrane, and is found in the extracellular matrix (ECM). TG2's known molecular roles include a pivotal role in the control of apoptosis, control of necrosis and repair of cell damage, roles in both up-and down-regulating a variety of fibrotic and inflammatory processes, in wound healing, and in formation and remodeling of a variety of mesenchymal tissues. It is expressed in several splice variants that have significantly different cellular and disease state distributions [28] [29] [30] : the extent to which different splice variants have different extracellular roles is not known. Because of this multiplicity of function, correlating TG2 levels with any physiological outcome is only the start of understanding what the protein is actually doing.
Intracellular and extracellular TG2 levels are strongly linked in several cell types [31] . The mechanism for exporting TG2 to the ECM was until very recently largely unknown, as it has no classical signal peptide to mark it for export. Studies in muscle cells suggest an excretion pathway involving TG2 cross-linking itself into microparticles, which are then released [32] through a common but poorly characterized pathway [33] . Microparticle release has been most studied in the cardiovascular system, where microparticles are released that contain high levels of cytokines and TG2 in aging microRNAs, and are associated with inflammatory, auto-immune disease and atherosclerosis [34] . TG2 is also associated with inflammatory, auto-immune and atherosclerotic disease, which is probably not a coincidence.
The cross-linking enzymatic activity of TG2 creates cross-links between many proteins, although it is not indiscriminate. Extensive studies of the sequence specificity of TG2 show that it has some restriction on the sequence around glutamine, although the amino acids immediately flanking the Gln residue have little effect on the TG2 reaction rate [35] [36] [37] [38] . TG2 has almost no sequence preference for the sequence around lysine. (I note however that surface lysines in extracellular matrix proteins are twice as likely to be flanked by hydrophobic amino acids as expected by chance from the distribution of all exposed surface amino acids, and so we might expect some limited selectivity for a flanking hydrophobic environment in TG2. (WB unpublished observation.)) It is not known of the hydroxylysine residues in collagen can also be substrates for TG2. The chance that a specific glutamine and lysine pair will be cross-linked therefore probably depends more on steric effects than on sequence, i.e. whether the proteins are near enough to cross-link [39] . TG2 has been shown to favour linkages between glutamines and lysines in regions of the protein showing high disorder in crystal structures [40] , which supports the idea that the enzyme crosslinks side-chains with sufficient mobility to approach within linking distance.
TG2 has been demonstrated to link polyamines to some proteins under physiological conditions [41, 42] , and gamma-glutamyl linked polyamines have been detected in a variety of tissues (review by [43] ). These can form polyamine-bridged cross-links in vitro (Reaction 2b in Figure 1) [44], but it is not known the extent to which cross-links formed in vivo are direct lysine-glutamine (epsilon (gamma-glutamyl) lysine -EGGL) cross-links or involve polyamines. The amounts of various polyamines, such as putrescine, spermidine and spermine, in the ECM normally are very low [45] , so EGGL is believed to be the major TG2-catalysed crosslink in the ECM [19] .
Regulation of TG2
Discussion of the regulation of TG2 is important for our purposes, because much of the research on TG2 and its role measures protein levels or enzyme activity, not cross-link levels. TG2 is expressed abundantly in many tissues, but most of the intracellular and extracellular protein is not an active transglutaminase [46] , indicating tight control of enzyme activity. (Note that TG2 is multifunctional, so lack of transglutaminase activity does not mean that the protein is biologically inert -it could be carrying out its other functions while its transglutaminase activity is inhibited.)
Purified TG2 requires about 1mM Ca
2+
for activity [26, 47] , although this requirement can be reduced to as low as 5uM in presence of substrate and other proteins, depending on the substrate [48] . GTP and GDP are allosteric inhibitors of TG2 [49] , stabilizing the compact, inactive form [50] [51] [52] [53] and GTP is hydrolyzed by TG2, although this is not part of the cross-linking chemistry. The binding of GTP or GDP reduces TG2 affinity for Ca 2+ . Thus inside the cell, with very low Ca 2+ and significant GTP levels, TG2 is expected to be inactive. However binding to other proteins, proteolytic processing or alternative splicing may all reduce sensitivity to GTP (reviewed in [48] ). TG2 transamidation activity is also reduced by S-nitrosylation by nitric oxide (NO) [54] in a Ca 2+ concentration-dependent manner [55] , and high levels of Ca 2+ caused release of NO from TG2, providing another part in the mechanism of TG2 activation. TG2 in aging
In the ECM Ca 2+ levels are typically higher than inside the cell, with normal concentrations ranging from 1.0-2.5 mM depending on tissue and physiological circumstance [56] [57] [58] [59] [60] Recently is has been found that TG2 is modulated by redox, through rearrangement of a disulfide bond between three cysteines outside the catalytic site. Oxidation can lock the enzyme into an open but inactive form. [48, 70] . The redox reaction is reduced by the presence of Ca
. It seems likely that TG2 is controlled through several pathways in the ECM, making predictions of its activity impractical.
The half-life of TG2 is relatively short, with an average of 11 hours [26] . TG2 gene expression is increased by retinoids [71], reactive oxygen species (ROS) through pro-inflammatory cytokines [72] and steroid hormones such as vitamin D and progesterone [73] . Other steroid hormones such as glucocorticoids seem to reduce its expression. This is consistent with a major role of TG2 in chronic inflammation. Additionally, Ca 2+ seems to promote TG2 proteolysis, while GTP appears to inhibit it [53, 74] stabilizes, is more proteolytically labile. In addition, any physiological change that increases protease levels or decreases protease inhibitor levels may change TG2 turnover.
The regulatory paths around TG2 catalytic activity are summarized in Figure 2 . An important conclusion from this wealth of regulatory data is that the presence of TG2 protein in the ECM (and even more so the presence of TG2 protein or mRNA in cells) does not imply that cross-links are being formed in the ECM. The only effective way to detect TG2 activity is with fluorescent irreversible inhibitors which directly test for transglutaminase catalytic activity (e.g. Dansyl Cadaverine -DC). Active TG2 cross-linking enzyme activity detected in this way outside cells may, with caution, be taken as an indication that EGGL cross-links are being formed in the ECM. Additionally, absence of TG2 protein or mRNA does not necessarily mean the absence of extracellular EGGL cross-links, nor that cross-links are not being formed, as other transglutaminase enzymes may form extracellular crosslinks, especially Factor XIIIA as noted below.
TG2 and the ECM
TG2 is able to crosslink a variety of proteins, both cytosolic and extracellular. Those that are important for the ECM of various tissues include collagen, elastin, fibronectin, fibrinogen, laminin, LTBP-1, nidogen, osteocalcin, osteonectin, osteopontin and vitronectin [26] . TG2 cross-links help TG2 in aging define structure of elastic fibers [76] by aligning the proteins. TG2 has a high binding affinity for fibronectin [77] , which is crucial for cell spreading, adhesion, and wound healing [78] , although this role may not involve TG2 catalytic activity [79] . Osteonectin cross-linking by TG2 also seems to be important for cartilage development [80] .
Several types of collagen can be cross-linked by TG2: cross-links are formed between the globular portions of the collagen molecule, not the triple-helical segments [19, 81] . TG2 cross-linked collagen is less ordered and more protease-resistant than collagen cross-linked by Lysyl Oxidase, consistent with its role in pathology rather than normal development of the ECM, discussed below. Type III collagen can be bound to the diamine putrescine by TG2 [82] and it is possible that this conjugate might go on to form N,N-bis(γ-glutamyl)diamine crosslinks. Some research suggests that some other collagens, such as types I and IV, appear to be poor TG2 substrates [81] .
'Healthy' functions of transglutaminases
As our goal is to consider TG2 as a target for therapeutic intervention, we must consider the positive, healthy roles of TG2, and of the transglutaminases in general, to gain some understanding of potential adverse effects of blocking TG2 action or undoing its effects by cleaving EGGL crosslinks. This section only summarizes a large body of work on TG2 in health and disease: the reader is directed to the references for more detail on the many roles of this multifunctional protein.
Role of transglutaminases
Transglutaminases are essential enzymes for healthy growth and development in mammals. FactorXIIIa was the first transglutaminase discovered, and is central to the blood clotting cascade. Genetic deficiency in FactorXIIIa causes severe clotting disorders in man [83] . As noted below, Factor XIIIa also probably has a role complementing TG2.
TG-1 and TG-3 [84] have a central role in assembling cornified cell envelope in stratum corneum, the outermost layer of the epidermis [85] . Epidermal TG is mainly in the granular layer of the epidermis, where terminal differentiation of the keratinocytes leads to development of the stratum corneum. One of the cross-linked proteins is fillagrin, whose mutation compromises skin barrier function and predisposes carriers to atopic dermatitis [86] . Homozygous TG1 knockout mice suffer severe dehydration from a few hours after birth [87] , and often die. Those that survive show massive keratosis (thickening of the upper layers of the skin) which partially compensates for loss of barrier function in the skin [88] . Human mutants of the gene suffer the life-threatening lamellar ichthyosis, a disease of profound disordering of the skin [89] . Transglutaminases are also important in providing mechanical strength to epithelial surface of lung alveoli [90] .
TG2 is known to be expressed abundantly in muscle development, especially cardiac muscle, during development in man [91] . However, as noted below (Section 3.4), it is not clear whether it is formally essential in this role.
Wound healing TG2 in aging
TG2's transglutaminase activity has an important role in would healing, and the enzyme is elevated in healing wounds in cell culture [46] and in vivo [92, 93] . Initially TG2 activity is a result of activation of previously inactive enzyme, not synthesis of new protein, but smooth muscle cells, fibroblasts and myofibroblasts all synthesize new TG2 in the ECM of the healing wound [94, 95] . TG2 stabilizes the matrix forming in the wound as cells move in and replace the original clot matrix (itself stabilized by Factor XIIIA cross-linking). Collagen fibrils laid down in the wound by myofibroblasts are cross-linked by TG2 [26, 93] .
Abnormal wound healing responses, notably hypertrophic scar formation, is associated with elevated TG2 [96] . Putrescine, a known inhibitor of TG2, has been tested as a treatment to prevent hypertrophic scar formation, but did not work (Procyon Biopharma press release Jan 18 th 2005).
Transglutaminase activity may also important in healing wounds in other tissue. In nerve axon injury, the axolemma (the cell membrane surrounding the axon) fails to seal after injury in low extracellular calcium [97] -calcium triggers a number of enzymes [98] , and this may include TG2. The role of TG2 in normal wound healing fits with its pathological role in fibrotic diseases, discussed below.
Intracellular roles and apoptosis
TG2 has a major role in the induction and control of apoptosis. A common signal for apoptosis is the influx of calcium into the cell, which will inherently activate the catalytic activity of TG2 [48] . Different isoforms of the enzyme have different effects, and TG2 in the cytoplasm has different effects from that in the nucleus (reviewed in [99] ). Activity of TG2 in apoptotic cells appears to cause massive cross-linking of intracellular proteins [25, 52, 100] , probably to keep the dying cell intact and to prevent leakage of cell contents into the extracellular milieu.
TG2 has been implicated in many aspects of cancer biology, including cell migration and the evasion of apoptosis that cancer cells achieve. As the focus of this review is effects in the extracellular space, these important aspects of the role of TG2 in cancer biology will not be discussed further here: the interested reader is directed towards recent reviews in the field [27, [99] [100] [101] [102] [103] [104] [105] .
A number of studies show that inhibiting transglutaminases with irreversible inhibitors such as DC blocks internalization of extracellular ligands or their receptors in cultured cells (e.g. see [106] [107] [108] ). DC blocks clustering of receptors in coated pits, which is therefore likely to be mediated by the catalytic activity of TG2 [106] . TG2 is also involved in phagocytosis in macrophages [109] .
Effect of genetic ablation of TG2
Given this diversity of role, it would be expected that mice in which both copies of any of the transglutaminase genes have been knocked out would exhibit multiple, severe morbidities. As noted above, homozygous knock-out (KO) mice lacking TG1, TG3 or Factor XIIIa [87] do suffer severe defects of the appropriate tissues or organs. TG2 in aging However two independently derived TG2 KO mice strains both show no overt pathology [110, 111] . The homozygotes are born at expected Mendelian frequencies, suggesting little prenatal mortality. Despite the widespread expression of TG2 in musculoskeletal development [91] , no obvious musculoskeletal abnormalities are seen in TG2 KO mice, apparently because Factor XIIIa can replace TG2 in musculoskeletal development [112] . Despite the role of TG2 in wound healing, TG2 KO mice are reported to show similar post-surgical wound healing to normal mice [113] , although others report defects in wound healing models [114] . Despite the widespread importance of apoptosis in many aspects of development and the proven role of TG2 in apoptosis, no abnormalities are seen in TG2 KO mice that can be traced to poor or excessive apoptosis in development. Fibroblasts from the mice showed reduced adherence in culture, and thymocytes from the KO mice induced to apoptosis died off faster. There are some abnormalities of macrophage function clearing apoptotic cells in some models [109] , but not others [111] . TG2 KO mice show a variety of changes in disease models, noted below, but in general are astonishingly healthy for animals that have lost a ubiquitously expressed, multifunctional protein. De Laurenzi et al [111] and Johnson et al [115] attribute this largely to the ability of other transglutaminases, notable TG1 and Factor XIIIa, to "step in" and take over TG2's role in a variety of normal physiological processes.
Extracellular TG2 cross-links and age
Levels of TG2 protein and mRNA have been measured in a wide variety of animals, diseases and ages, but relatively little of this work has addressed protein cross-linking. This section will focus on the ECM, and touch on other aspects of TG2 only when needed to dissect the overall pattern of TG2 presence of activity from its role in the mechanical properties of tissue.
Evidence for EGGL accumulation with age
There is very little information on whether EGGL cross-link densities change with age, other than in direct association with a disease or pathology. What evidence there is suggests that EGGL may increase with age in the absence of overt pathology, but methodological issues dog these studies. A range of antibody tests have been suggested [90] [94, 116, 117] , but a recent survey suggests that many of the antibodies to EGGL cross-react with other antigens (Ustok et al in preparation), and those that are specific may not detect cross-links efficiently when they are embedded in a dense protein matrix [118] . Measuring TG2 catalytic activity is a common substitute for measuring EGGL, but TG2 catalytic activity will only correlate with relative EGGL levels if protein turnover is the same between the compared states, and if TG2 is the only transglutaminase forming EGGL in that tissue. In most non-diseased tissue, the majority of the transglutaminase activity is generally believed to be TG2 (although Factor XIIIa is seen to substitute for TG2 functionally in many circumstances, as noted in Section 3.4 above, so TG2 cannot be assumed to be the only extracellular transglutaminase.) As protein turnover is different in many of the diseases discussed below, transglutaminase activity can only be regarded as a semi-quantitative indicator of likely EGGL levels.
As noted above, much of the TG2 in the ECM is catalytically inactive, so measuring TG2 protein levels is only very circumstantial evidence of cross-link densities. Direct chemical measurement of EGGL is complex and time-consuming, and so rarely performed, but it is possible to TG2 in aging simultaneously measure lysine and EGGL levels, and thereby obtain cross-linked lysine residues as a percentage of total lysine [119] . Even chemical measurements of EGGL do not provide data that can be compared between studies. Studies report EGGL as a fraction of total lysine, of collagen, of protein or of tissue mass without providing the data on the ratios of lysine to collagen to protein to tissue mass that would allow inter-study comparisons. The data set is therefore poor.
One study has shown clearly that EGGL levels increase with aging in healthy humans in arterial walls, as evidenced by immunohistochemical staining which showed an approximate 2.5-fold increase in staining in aged human subjects compared to young ones [54] . This correlated with an increase in TG2 activity of approximately 75% from young to aged subjects. Similar increases were observed in rat aorta. Other work in the same report shows that at least some of the increase in stiffness in mouse artery with age is attributable to increase in TG2 activity, caused both by increase in protein expression and decrease in inhibition by NO. The mechanism for this increase was determined to be decreased S-nitrosylation of TG2, likely because of decreased NO bioavailability in the ECM with aging [120] . TG2 protein levels did not change significantly in this study, consistent with an activation of pre-existing enzyme.
Nemes et al [121] also show that EGGL-cross-linked proteins are present in significantly higher levels in old, healthy human brains compared to young brain tissue. However we should note that 'healthy' old brains often show signs of neuronal loss, beta amyloid accumulation and other molecular markers of neurodegenerative disease even if overt cognitive or behavioral symptoms are not seen, so it is unclear what a 'healthy' brain actually looks like in this context. It is also not clear how much (if any) of this EGGL was extracellular.
Suzuki et al [122] show data suggesting that EGGL cross-links in stratum corneum decline with age, which may be related to the changes in barrier function of skin with old age (reviewed in [123] ). As this is a specifically differentiated tissue, it is not representative of the ECM elsewhere, although aging of skin is itself a significant issue. Skin EGGL is primarily laid down by TG1 and TG3, not TG2, in normal skin growth.
Several studies examine the EGGL cross-link as an isolated entity in serum or urine. These are interesting (especially in the diagnosis of neurodegenerative disease, discussed below) but are not helpful to our quest. Serum and urine EGGL derives both from turnover of ECM and from intracellular cross-linking and subsequent breakdown of proteins associated with apoptosis. It therefore is a marker of tissue turnover, not stable EGGL levels, and is only tenuously related to ECM EGGL. For example, collagen cross-link excretion is elevated 1.5-to 2-fold in young, fit, healthy men during space-flight due to loss of bone and muscle loading and consequent increase in tissue turnover. Excretion returns to normal on landing [124] .
Evidence for increase in TG2 activity with age
TG2 activity is easier to measure than EGGL cross-links, and as consequence a range of studies have looked at protein levels or enzyme activity rather than cross-links accumulation. As noted above, this is indicative of cross-link densities only. TG2 in aging Some studies in human tissue show increase in TG2 or transglutaminase activity with age in absence of pathology. Normal (non-arthritic) knee meniscus tissue and chondrycytes show an increase of TG2 activity with age [125] (as well as an additional increase with disease, as noted below). A range of animal studies have looked at TG2 levels in different species and tissues. In general, they find an increase of TG2 catalytic activity with age. Total rat liver TG2 activity increases about 1.5-fold (with substantial variation) between young and old animals, while levels in the brain increase 7-fold in a much more systematic pattern [126] . TG2 mRNA however does not increase in rat brain with age: if anything there is a slight decrease [127] . Total TG2 levels are found to be elevated in old vs. young pig articular chondrocytes [128] . There is an increase in TG2 in the macrophages of old vs. young mice [129] , which however may be related to a higher background level of immune activation in old mice. TG2 levels in murine macrophages are also found to vary between strains, so the generality of age-related effects is unknown. As noted above, rat aorta shows an increase in TG2 activity with age [54] . In rat kidney TG2 mRNA increases with age in male but not female rats, which is probably related to testosterone induction [130].
Changes in substrate availability
The availability of substrates for transglutaminases may change with age -in general, these changes suggest that the potential for ECM proteins to be cross-linked by transglutaminases may decline with age rather than increase.
Glutamine spontaneously deamidates over time, especially when in a Gln-Ser or Gln-Gly sequence [131, 132] . Aspartate and asparagine racemization is a feature of the same chemistry: D-aspartate can be expected to make up 10% of aspartate in elastin in the tendon and aortic walls of a 50-yearold human [133] , so removal of accessible glutamines may significantly reduce the substrate availability in old tissue. Some studies show that polyamines decline with age [134] , others suggest that they do not [135] . Polyamine-supplemented diets have been suggested to reduce age-related kidney and liver function decline [136] , although the rationale behind this, while passionately defended by some, is not generally supported.
ECM proteins probably change with age, but quantitative specifics are limited. Collagen levels increase with age in mouse [137] and rat [138, 139] models of muscle ageing, but are not significantly changed in human muscle [140] and decrease in human skin with age [141] . Collagen packing may become less dense in some tissues with age, reflecting different organization [142] this may affect all forms of collagen cross-linking, as proteins have to be physically near to each other in the ECM to be cross-linked. The organization of other proteins has not been systematically measured.
EGGL and long-lived proteins
Accumulation of cross-links is the result of a balance between their synthesis and their removal. EGGL could accumulate because its rate of synthesis increased with age, as implied by the sections above. Or it could increase because its rate of removal declined, or (equivalently) was so slow that EGGL, once made, stayed with you forever. Either could lead us to expect EGGL levels to rise with age. TG2 in aging Enzymes that cleave the isopeptidase bond in EGGL would be classed as isopeptidases. While such enzymes are known in non-mammalian species (discussed in section 5.2), it is generally believed that there is no human isopeptidase that cleaves the EGGL link in the ECM. The body removes extracellular EGGL by proteolysis of the cross-linked protein as part of ECM turnover and remodeling, and then cleavage of the isolated EGGL. Gamma-glutamylamine cyclotransferase (GACT) can cleave isolated EGGL [143, 144] converting EGGL to free lysine and 5-oxoproline (Reaction 6 in Figure 1 ). It is quite non-specific to the lysine moiety, acting on D or L lysine and on other, non-amino acid side chains with more than three methylene groups. The enzyme can also accommodate quite bulky substituents on the lysine analogue [145] . However GACT only acts on the free isopeptide, not on cross-links in proteins. Another enzyme, γ-glutamyltransferase (GT), a membrane protein with an extracellular active site [146] has been found to liberate free lysine and glutamic acid from the EGGL crosslink during gastrointestinal digestion of cross-linked protein [147] . Over-expression of GT has been linked to increased risk of tumor growth and metastasis [148] , as well as osteoporosis [149] . 5-Oxo-L-prolinase, an enzyme widely distributed in mammalian tissues, catalyzes the conversion of 5-oxo-L-proline back to L-glutamate (reaction 7 in Figure 1 ) [144] .
Loewy [150] used a TLC-based assay to report the identification of isopeptidases in a variety of organisms from B. cereus to chicken brains, and claimed widespread enzyme activity in mammalian tissues including brain [151] . However this work was never followed up, so it is not possible to confirm that this activity is due to a general EGGL-cleaving enzyme. Their assay may have been detecting the intracellular isopeptidases that cleave the isopeptide bond between ubiquitin and proteins targeted for proteosomal destruction (Isopeptidase T), which is known in many cells and all species [152] . This enzyme is quite specific, and (as far as is known) will not cleave EGGL links between matrix proteins.
Thus EGGL itself is not turned over with age. If EGGL accumulates with age, it is most likely because the proteins in which it is placed do not get turned over.
Some proteins are extremely long-lived, being turned over very slowly. Radiotracer experiments tracking the isotopes incorporates into children's eye lens crystalins in the late 1940s and early 1950s (when atmospheric testing of nuclear weapons performed a 'pulse chase' radiolabelling of every human then alive) suggest that some of the crystalins of the lens of the human eye are not turned over at all [153] . Aspartate racemization measurements suggests that the collagen in articular cartilage has a half-life of at least 70 years [154, 155] , and that of human skin collagen as ~14 years. Aspartate racemization studies suggest that collagen in bone and teeth also contain longlived proteins. Other Asp-racemization determined half-lives include Agretecan in intervertebral discs (~11 years) [156] , elastin in skin elastic fibres (at least a year, varying substantially with age) [157] , and bone osteocalcin (at least 50 years) [158] . Total protein in bone, skin, brain, teeth and eye all show systematic increase in D-aspartate levels with age.
Aspartate racemization data should be viewed with care. The rate of aspartate racemization is sequence-and structure-dependent. Different proteins (including different collagens) will generate D-asp at significantly different rates, and proteins which have limited peptide backbone mobilitydue to native folding, amyloid formation or cross-linking -will have substantially lower rates of aspartate racemization than ones that are naturally flexible, or are denatured [131, 132, 159, 160] . TG2 in aging
We should also note that the D-Asp levels are often measured in 'acid-insoluble' fractions of tissue, and some cross-links are acid-unstable, so proteins will be selectively lost through this preparation method. However aspartate racemization studies do suggest that some ECM components have halflives of years, possibly decades, and so EGGL cross-linking them may last for years or decades as well.
The ECM is turned over slowly as a whole (apart from large-scale replacement after wounding or severe pathology). Replacement ECM is often less well organized than the original (reviewed in [161] ), and so may be more susceptible to TG2 cross-linking. In general, protein turnover is observed to decline with age (reviewed in [162] ), along with the general metabolic slowdown of the elderly. ECM turnover declines significantly with age in intervertebral discs [163, 164] and articular cartilage [165] , although apparently not in muscle, where exercise and diet dominate collagen synthesis rates [166] . Disease states (such as the tendinopathies discussed below) can however substantially accelerate ECM turnover, as can loading changes and other factors [124, 167, 168] .
It is plausible, therefore, to suggest that TG2 action to create EGGL cross-links in tissue will increase the level of EGGL for some time afterwards, and possibly for a substantial proportion of the individual's life. In the next section, I consider the information on TG2 activity in the context of age-related disease, which could provide the episodes of EGGL formation necessary to create cross-links in these long-lived proteins.
TG2 in age-related diseases
In contrast to the paucity of data on EGGL cross-links in aging in the absence of specific pathology, there is a wealth of data on EGGL, TG2 activity and TG2 protein in specific disease states. I will summaries these briefly, both because specific diseases contribute to the disabilities of old age and because they suggest mechanisms that will drive cross-link formation and accumulation in "healthy" aging.
TG2 is likely to have at least three roles in cancer, as a modulator of apoptosis and cell autophagy, changing the ECM to enable cell transformation, and as a modeler of the ECM through which cancer cells must migrate. However this is not a potential role of TG2 in "healthy" aging or in the chronic diseases of old age, and so I will not discuss TG2 and cancer in this paper. The role of TG2 in cancer, and the potential of TG2 as an anti-cancer therapeutic target, has been discussed extensively elsewhere (see [101, [169] [170] [171] [172] [173] [174] and references therein)
TG2 in inflammatory and autoimmune disease
It is often stated that TG2 activity is elevated in inflammatory and immune diseases (see e.g. [174] [175] [176] ). The actual picture is more complex, and TG2 activity and EGGL accumulation is better thought of as a feature of fibrotic diseases that result from chronic inflammation or other insult. TG2 and EGGL levels have either not been examined, or have been examined and been found to be unchanged, in a range of inflammatory diseases. In particular, citations in reviews to papers on diabetes [177, 178] and rheumatoid arthritis [179] are actually referring to studies showing TG2 in aging elevation of anti-TG2 autoantibodies, not TG2 itself or its cross-links. It is therefore important to identify which disease, aetiology and underlying mechanisms are relevant to our quest.
Some chronic inflammatory diseases show clear elevation of TG2 expression, protein, catalytic activity or EGGL cross-links. TG2 expression is elevated in a range of inflammatory myopathies [180, 181] , where it is seen specifically in damaged and regenerating muscle fibres [182] . TG2 is a marker of osteoarthritis disease severity in guinea pig [183] , and significant levels of TG2 activity and cross-links are reported in human osteoarthritis [125, 184] , although without comparable control levels in normal knees. In asthma TG2 protein and protein cross-linking are all elevated [185, 186] . (I note that chronic asthma has many of the features of a chronic fibrotic disease: reviewed in [187] ). High levels of TG activity and cross-linking in psoriasis are probably related to skin-specific transglutaminases, not TG2 [188] . It is worth noting that wound healing in adults has a substantial inflammatory component: hydration of skin (i.e. support of the barrier function) reduces this [189] (reviewed in [190] ).
We should note that intracellular TG2 activated post-translationally by ROS in a TGF-β related mechanism [191, 192] , so the role of TG2 in inflammatory disease is not solely extracellular, and rise in EGGL in a tissue may represent intracellular activity, not ECM cross-linking.
Sohn et al [193] used a TG2 inhibitory peptide which could not enter cells to block inflammatory uveitis, and [175] used the same peptide to reduce the effect of a murine model of asthma, demonstrating that at least some of the role of TG2 in this model was outside the cell (although the peptide also has PLA2-inhibitory properties [194] , so its action can be unambiguously attributed to TG2 inhibition). Generalized immune activation in mice by LPS injection in mice can cause increase in TG2 activity and EGGL in a variety of tissues on different timescales [195] . However different inflammatory inducers can produce septic shock models that are enhanced or reduced byTG2 knockout, depending on the inducer [196] , illustrating that this is a complex and highly non-linear system. Extracellular TG2 is inactive in the small intestinal mucosa of mice until stimulated by poly(I:C) (mimicking viral infection) [46] . Morbidity in Poly(I:C)-treated mice was substantially greater in TG2 KO mice than in controls [197] , suggesting a protective role for TG2 in acute inflammation.
TG2 has a unique role in celiac disease, where it is the auto-antigen against which the immune system reacts [198, 199] . Anti-TG2 antibodies highly diagnostic of the disease [200] [201] [202] . Gliadin peptides from wheat gluten are an excellent substrate for TG2, which may result in TG2 crosslinking itself to gliadin [203] , thereby sensitizing the immune system to the enzyme which is then removed, stopping the formation of effective tight junctions along the intestinal mucosa [204] .
Auto-antibodies against TG2 are reported to be common in some other inflammatory diseases, although not at the level found in Crohn's Disease (reviewed in [176] ). However Sánchez et al [205] report looking for auto anti-TG2 IgA antibodies in Lupus, Type I diabetes, Multiple Sclerosis, autoimmune thyroiditis and non-Crohn's inflammatory bowel disease, and seeing no difference from controls. There is a gradual increase in TG2 autoantibodies with age in healthy people (although to much lower levels than in Crohn's Disease) [206] . This might suggest that TG2 TG2 in aging activity levels are reduced with age in the absence of disease, as the enzyme is cleared by the immune system.
TG2, Advanced Glycation Endproducts, and immune changes
As well as overt immune or inflammatory disease, EGGL synthesis might be enhanced with age as a result of the increase in 'background' inflammation with age, arising from two causes: Advanced Glycation Endproducts (AGEs) and inherent immune decline.
High glucose, high insulin and advanced glycation endproducts (AGEs) can increase TG2 activity. [207, 208] . Reactive Oxygen Species (ROS -molecules such as superoxide and hydrogen peroxide) can increase the expression of TG2. As AGEs can act as pro-inflammatory mediators by binding to the Receptor for AGEs (RAGE) [209] and thereby increasing the production of ROS [210] , AGEs could have an indirect effect on transglutamination. The accumulation of AGEs with age is well known [3, 17, 211, 212] , and so it is expected that this mechanism would increase TG2, and hence EGGL, with age. The link between TG2 and glucose metabolism may be a major factor driving the link between TG2 and diabetic nephropathy (Section4.5.3).
The immune system itself declines with age (reviewed in [213] ), and as a major function of the immune system is to keep itself in check, we might expect inflammatory activation to rise with age, However the evidence for increases inflammatory damage resulting from immune dysregulation is more mixed: PMN cells and NK cells appear to be as functional in the elderly as in the young [214, 215] , and if anything to have lower levels of activation to generate ROS. If there is an immunerelated increase in TG2 activity, and hence EGGL synthesis, with age, it is likely to be a result of other chronic damage such as AGE accumulation rather than decline in immune function.
TG2 and fibrosis
Much of the reported role of TG2 in inflammatory disease can be attributed to its role in fibrosis, the excessive or aberrant accumulation of extracellular material in reaction to inflammation. TG2's role in fibrosis fits with its role in wound healing and scarring, as fibrosis is considered an abberant or over-exuberant wound healing response, often to inflammatory injury (reviewed in [216, 217] ). A major role of TG2 in inflammation appears to be to control the effects of cell death, by crosslinking cellular components to stabilize them against release and induction of inflammation and bystander cell killing. TG2 knockout mice have reduced clearance, enhanced tissue toxicity and enhanced inflammatory reaction in liver cirrhosis models [109, 218] . TG2 knockout mice have fewer Mallory bodies (intracellular cross-linked protein bodies accumulated in some liver diseases) than normal mice, and higher levels of gallstones, jaundice and ductal abnormalities in a model of liver damage, suggesting enhanced cellular damage [219] . TGF beta both stimulates macrophages to clear apoptotic cells and induces TG2. In this regard it is interesting that TG2 activity tends to rise in early stages of animal models of hepatitis, and decline later when lysyl oxidase cross-links are more abundant in the fibrosis [220] , implying TG2 has a transient stabilizing influence. Hepatitis studies are complicated by TG2's role in the apoptosis of hepatocytes in many disease models [99, 221] . TG2 in aging Fibrotic diseases commonly are caused by chronic tissue damage and associated inflammatory processes that over-induce these protective mechanisms. TG2 over-expression is a feature of the renal scarring that is associated with chronic kidney disease in man [31] and in streptozotocininduced diabetic rats [222] , where EGGL levels rose 8-fold in 120 days. Inhibitors that specifically target extracellular TG2 reduce fibrosis and scarring in an animal model of diabetic nephropathy [223] and kidney fibrosis [224] . TG2 knock-out mice have reduced fibrosis in a model of idiopathic lung fibrosis [225] , due in part to reduction of the NF-KB pathway [226] , and there is strong correlation between TG2 levels, EGGL and nephrosis in man [226] .
As well as diseases where fibrosis builds up in normally non-fibrous tissue, TG2 is implicated in diseases where tensile connective tissue such as tendon or cartilage is injured. Tendinopathy is a particularly important case for aging, as the collagen in tendons has a very long half-life in man as noted above, and so could be a candidate for mechanism (3) in Section 1. TG2 is elevated in rotator cuff tendinopathy [227] , although TG2 gene expression may paradoxically be reduced in ruptured tendons, with elevated TG1 and Factor XIII compensating [228] (again, speaking to TG2 activity as a sequela of injury rather than a cause or immediate response to it). We can note also that cataract formation is probably accelerated by transglutaminase cross-linking of lens crystalins [229] , probably as a result of inflammatory damage to proteins and/or induction of transglutaminase [230] (reviewed in [20] ).
Cardiovascular and metabolic disease
TG2 is associated with a wide range of cardiovascular systems and processes, including modulating platelet activity, contributing to the development of hypertension, influencing the progression of atherosclerosis, regulating vascular permeability and angiogenesis, and contributing to myocardial signaling, contractile activity and ischemia/reperfusion injury (reviewed in [231] ). TG2 activity is associated with arterial stiffening in man [232, 233] and rats [234] . Remodeling of small arteries, which is dependent on TG2, [235] is defective in TG2 KO mice [113] . . EGGL concentrations are elevated in atherosclerotic plaque in man [236] although the enzyme forming cross-links is Factor XIIIa, not TG2 [237] . ApoE/TG2 double KO mice did not show any effect of TG2 on plaque chemistry or stability [238] , suggesting TG2 elevation is an effect and not a cause of atherosclerotic pathology (ApoE KO mice can be driven to develop atherosclerosis rapidly on high-fat diets.) However pharmaceutical blockade of TG2 and FXIIIa reduces macrophage infiltration in atheroscleoric lesions in mice [239] , suggesting the reverse. Mice engineered to express high levels of TG2 show enhanced cardiac hypertrophy and fibrosis and apoptosis under stress, an effect in which elevated TG2 interacts with COX-2 and is modulated by COX-2 inhibitors [240] . However it is not known if this is dependent on the transglutaminase activity or G-protein activity of the TG2 protein [241] .
TG2-catalysed protein cross-linking is also elevated intracellularly in the heart during the damage that occurs after after ischemia and reperfusion (called reperfusion injury) [242, 243] , although this effect is related at least in part of changes in mitochondrial energy metabolism and changes in the TG2 in aging mitochondrial arm of the apoptotic response [109, 244, 245] , and may also be related to TG2's protein disulfide isomerase activity [23, 246] .
The majority of these effects can be seen as an extension of TG2's role in inflammatory disease. Atherosclerosis and reperfusion injury have strong immune components, and TG2's role in them may therefore represent a response to, or perhaps over-compensation for, inflammatory disease.
Neurodegenerative disease
The association of TG2 cross-links and EGGL with neurodegenerative disease, especially Alzheimer's Disease (AD), is well-known [103, [247] [248] [249] . EGGL [247, 250] and TG2 [251] are found in the CSF of AD patients at levels significant higher than those in normal patients although not in the CSF of patients with vascular dementia [252] . EGGL and TG2 are elevated in a mouse model of Huntingdon's disease model [253] but the course of the disease is the same in TG2 + and TG2 -mice [254] . TG2 is elevated in human HD patients brains [255, 256] , and in serum and CSF (but not spinal chord) of early stage ALS patients [257] .
This association of TG2 activity is likely to be related to neuronal cell death. As mentioned, TG2 is strongly implicated in apoptosis [258] , and neuronal cell death is a major feature of AD. Thus much of the EGGL and TG2 in neurodegenerative disease is likely to be a marker for cell death, not extracellular effects. (The same caveat applies to the studies above noting increased TG2 levels in old, 'healthy' animal brains.) TG2 does induce rapid aggregation of amyloid beta (Aβ) protein in vitro at physiological Aβ concentrations, whereas Aβ aggregation without TG2 required much higher Aβ concentrations [259] . TG2 can crosslink Tau protein into aggregates [260, 261] , and EGGL cross-links are found between tau tangles and beta amyloid [151] .
There may nevertheless be a relationship between extracellular transglutaminase or EGGL and neurodegenerative disease. I note a preliminary report of an intriguing link between progression of Amyotrophic Lateral Sclerosis and reduced skin elasticity [262, 263] . This has not been formally reported, and the informal report suggests that there are a range of biochemical changes in skin causing the mechanical changes: cross-linking was not reported explicitly. However it would be worth exploring whether extracellular EGGL metabolism was abnormal in this neurodegenerative disease in skin and spinal tissue.
Conclusions: EGGL, TG2 and aging
The picture is, to say the least, not clear. Inflammatory, autoimmune and fibrotic diseases all have an immune component, as does chronic arterial disease. The role of TG2 in these diseases is consistent with its role in modulating tissue damage following immune activation, and hence its pathological role is related to over-activity in this mode.
There is some limited evidence that EGGL increases with age, independent of its (short-term) increase in specific, overt disease. However discriminating as to why this happens is hard. In terms of the three options listed in Section 1, does EGGL TG2 in aging 1. inherently increase with the aging of tissue, independent of specific disease. There is little evidence for this, but this is mainly because it has not been studied. Changes in anti-TG2 antibodies and substrate availability suggest that TG2 activity (and hence EGGL accumulation, although not necessarily absolute levels) decreases with age. 2. increase with aging as a result of low levels of pathology that generally increase with age, without overt or florid disease. There is substantial evidence that EGGL is deposited in tissues by disease mechanisms that increase in incidence with age, such as chronic inflammatory diseases. 3. increase as a consequence of specific episodes of diseases (acute or chronic) that emplace cross-links in long-lived proteins. It is highly likely that long-lived proteins are cross-linked by TG2, and therefore that any extracellular TG2 activity will cross-link those proteins with EGGL that will accumulate with age. It is particularly likely that rising burden of inflammatory disease with age would deposit EGGL in a variety of tissues.
The rise of EGGL cross-links with age, and their effect on tissue elasticity, could be relatively easily checked by looking at the tissue physiology and biomechanics of TG2 knock-out mice in the absence of induced disease. As noted above, TG2 knock-out mice show no obvious (i.e. youngonset) abnormalities, and do show differences in models of age-related disease. Do they show differences in 'normal' aging (i.e. aging in the absence of an acute, induce pathology)? This would be an issue worth exploring.
What is not known is whether the rise of EGGL with age is quantitatively significant, or whether the other cross-links, such as AGEs or lysyl oxidase-formed cross links mentioned in Section 1 dominate ECM physiology. The evidence for the quantitative role of different cross-links will be reviewed elsewhere (Bains and Grainger in prep), but the data is not strong. There is no study of which I am aware quantifies the three classes of cross-link mentioned in Section 1 in the same tissue, so the relative levels of EGGL and hence their relative contribution to ECM stiffening are unknown. This is a major gap in the literature on ECM biology.
Therapeutic approaches
The analysis in Section 4.6 is not classification for the sake of classification. Excessive crosslinking of the ECM is probably a bad thing, which we might wish to avoid, block or remove. TG2 may contribute to this. But what is the best route to blocking or removing EGGL?
If EGGL accumulates in tissue because of continued, chronic increase in TG2 activity (option (2) above), then blocking this activity will reduce TG2 and hence EGGL levels, reversing the effect. Equally, blocking immune activation would also be effective. Evidence of the KO mice suggests that whole-scale blockade of TG2 may not have serious adverse effects. However if EGGL inherently accumulates with age, or accumulates in long-lived proteins as a result of past TG2 activity, then it will have to be actively cleared -blocking TG2 today will not reverse its effects yesterday. At the moment, we do not know which of these strategies might have value. The pragmatic approach is to try them all (an approach the pharmaceutical industry takes by default in TG2 in aging many disease areas, even if each company believes that their strategy is "the best".) But are all three equally practical?
Discussion of anti-inflammatory drugs is beyond the remit of this review: an entire literature exists on the therapeutic modulation of the immune system. Here I will focus on approaches to block TG2 activity and to remove EGGL cross-links.
TG2 inhibitors
TG2 inhibitors have been a research target in academia and industry for several decades, primarily because of TG2's role in cancer [264, 265] , but also targeted at neurodegenerative disease [266] . Approaches to developing TG2 inhibitors are to screen known compounds for (fortuitous) ability to block TG2, designing mechanism-based irreversible inhibitors, and designing conventional, reversible inhibitors for the enzyme's many binding sites.
The catalytic mechanism of the transglutaminases is well-known. The active site of TG2 and other TGs contains a so-called catalytic triad of amino acids, consisting of Cys-314, His-373 and Asp-396 [267] . This catalytic triad bears high similarity to the catalytic triad found in cysteine proteases [268] . Based on the mechanistic and structural understanding of the enzyme, substantial effort has been expended developing transglutaminase inhibitors (reviewed in [21, 102] ). Indiscriminate blockade of all transglutaminase activity is likely to be very harmful. So therapeutic development has focused on trying to produce isotype-specific inhibitors [21] . Many inhibitors that show strong blockade of enzyme activity have been demonstrated in the lab., but so far none have progressed to clinical development.
As noted above, gluten peptides are extremely good substrates for TG2. A range of inhibitors have been designed by modifying these with chemical groups that hijack TG2's mechanism and chemically link the inhibitor to the enzyme [269] . Typically, there are peptides or peptide mimetics with a reactive group on a side-chain instead of an epsilon amine group. Reactive groups have included epoxide, maleimide and diazo groups. Other irreversible inhibitors that are not based on peptides have also been designed [270, 271] .
Of the other binding sites on TG2, only the GTP binding site has been targeted by an inhibitor, Tyrphostin 47, an EGFR kinase inhibitor that binds to TG2 competitively with GTP [272] . Some kinase-related inhibitors of TG2 have been found, but are competitive inhibitors of enzyme activity [272] , not (as far as is known) allosteric inhibitors acting through the GTP site. For anti-cancer applications, inhibitors that are competitive with GTP may be particularly effective. Mutants of TG2 that cannot bind GTP strongly promote apoptosis [273] , suggesting that an antagonist of GTP binding might also be pro-apoptotic. As far as I know, the very extensive libraries of kinase inhibitors (reviewed in [274, 275] ) and GTPase inhibitors (e.g. [276, 277] ) have not been screened for activity as TG2 allosteric inhibitors. However some small libraries of compounds developed for other targets have been screened, and several found that inhibit TG2 at low nM potency, suitable for development as drugs [272] . TG2 in aging
Inhibitors that target the enzyme's active site only act on active protein, and so will not affect enzyme that is currently inactive. As much of TG2's activity is the activation of pre-existing enzyme, it is not clear whether this is a useful therapeutic strategy.
Inhibitors tested in animal models have proven effective in animal models of kidney fibrosis and scarring [208, 223, 224, 278] , and models of Crohn's disease [279] [280] [281] [282] . However none of these agents have come close to clinical development. This is probably because they have all been developed for specific, overt diseases for which other therapeutic approaches are precedented, and so preferred
EGGL removal agents
A more ambitious goal is to remove EGGL cross-links from the body. There are two approaches to removing EGGL cross-links from the ECM. The cross-links can be cleaved, releasing the crosslinked proteins, or the proteins as a whole can be degraded. As wholesale degradation of proteins in the ECM is clearly undesirable, this latter approach means that the natural turnover of proteins in the ECM must be stimulated. Enhancing turnover has been reviewed elsewhere in the context of removing glycation cross-links [283] , and will not be discussed further here.
Removal of EGGL itself is a more specific target. If TG2 crosslinks are found at high enough levels to play a major role in the age-related diseases of the ECM and other tissues in humans, it would be desirable to find a way to reverse their formation. This requires a chemical cleavage agent, or an enzyme.
Chemical cleavage of the isopeptide bond seems an unlikely possibility. Any reagent that could cleave the isopeptide bond would also cleave at least a small fraction of all of the peptide bonds in the body, rendering it extremely toxic. Targeting a peptide bond-cleavage agent to the isopeptide bond would require multiple interactions, effectively an artificial enzyme, which is beyond conventional drug chemistry.
Enzymatic cleavage is plausible and precedented. Isopeptidases are known to be produced by organisms that eat highly cross-linked proteins, such as the Brown House Moth which can live off the highly cross-linked keratin in wool [284] . Other organisms that live on materials that are highly cross-linked with EGGL (or indeed other cross-links mentioned in Section 1) may be fertile sources for specific isopeptidases.
Mammalian isopeptidases are known to exist, although none are suitable as ECM-opening agents without substantial modification. I have mentioned the intracellular isopeptidases that cleave the isopeptide bond between ubiquitin and proteins targeted for proteosomal destruction (Isopeptidase T) [152] . Isopeptidase T is specific to polyubiquitin, and so could not be used as a general EGGL cleavage agent in vivo, but engineering the protein for broader specificity might be practical. Thyroglobulin is cross-linked extensively in thyroid gland lumen, 20% to 70% of cross-links are EGGL depending on species [285] . Thyroglobulin has to be endocytosed to be broken down and thyroid hormones released, so large multimers must be broken down from 'globules' of protein before endocytosis. A plasminogen-like protein [286] and possibly cathepsin-like proteases [287] are involved in breaking up the very large cross-linked masses, and may be able to cleave the TG2 in aging EGGL links within them. As mentioned above GACT cleaves free EGGL crosslinks [143, 144] converting them to free lysine and 5-oxoproline. However GACT has a deeply buried active site [288] , which is only suited to cleave small molecule substrates and not peptides linked by EGGL cross-links. Thus, while we might think that a mammalian enzyme would be an easier starting point for developing a therapeutic, because it is less likely to be immunogenic, it is likely that the EGGL-cleaving enzyme from the House Moth will be a more practical target for protein engineering.
Therapeutic targets for EGGL removal
Developing any treatment for the disability of aging is an ambitious target. Apart from academic discussions of whether aging is a disease, a precursor to disease, or something that is part of our "normal" biology (like plague and starvation) [289, 290] , there is the more practical issue of what efficacy and toxicity endpoints would be acceptable for a clinical trial of a new drug aimed at reducing disability in older people who were not diagnosed with overt, acute pathology. It would ease the regulatory route for a treatment if it could be applied to a recognized disease or disorder for development, and then have its use extended once launched. This is a well-trodden strategy for drugs from aspirin to EPO. What would the initial therapeutic target be?
The evidence above suggests that TG2 has an effect cross-linking the ECM in a range of fibrotic disease. Reducing cross-linking in the walls of major arteries or the capillaries of the kidneys is liable to have toxicity risks, making it a high-risk strategy over other, more conventional treatment for cardiovascular disease and nephropathy. Targeting a non-life-threatening but disabling condition might provide a better risk-reward ratio for a developer. Two possible areas are cataracts and tendinopathy.
TG2 is plausible as a mechanism for formation of anterior polar cataracts. While TG2 is not the principle cause of cataracts (they are triggered by TGF-β mediated inflammatory processes), once TG2 has cross-linked lens proteins their extremely long lifetimes [153] means that the only plausible treatment is cleavage of the cross-links or removal of the lens. Treatment with an EGGL cleavage agent topically limited to the lens capsule by injection is plausible, and an interesting potential alternative to surgical replacement of the lens with a synthetic lens, as the restored lens would have some flexibility, also (partially) reversing age-related presbyopia.
Tendinopathies may also be an attractive therapeutic target. Over-use or inflammatory injuries to tendons, especially the rotator cuff tendons of the shoulder, result in substantial limitations of movement that can be partly relieved by long-term physiotherapy. Relaxation of the over-rigid tendon could benefit these patients, providing an overshoot did not render them liable to dislocation of the shoulder, which is extraordinarily painful and results in further inflammatory damage.
There is precedent for replacing surgical procedures with enzyme treatment. Dupuytren's Contracture is a disabling but not life-threatening pathology of the tendons of the palmar fascies of the hand, in which formation of fibrotic scar tissue around the tendons of the palm and fingers results in increasingly restricted movement of the affected fingers. It can be treated surgically, under general or (more rarely) local anesthetic as an outpatient procedure. However in 2010 collagenase from Clostridium histolyticum was approved as an alternative treatment. Collagenase is TG2 in aging injected into the fibrotic bands around the tendon, weakening them and allowing the surgeon to straighten the affected fingers [291, 292] . The procedure is faster and less invasive than surgerywhether it is as effective remains to be seen. But the precedent for replacing day surgery with relatively non-specific enzyme treatment has been established, and offers hope for an early path to an EGGL cleavage agent being developed as a therapeutic.
Conclusion
There is limited but encouraging precedence for extracellular TG2 activity and extracellular EGGL cross-links as therapeutic targets for the diseases and disabilities of aging. However substantially more work needs to be done to quantitate the level of cross-links, as opposed to relative TG2 enzyme, protein or gene levels, both in disease conditions and in aging in the absent of acute pathology. A significant and major lack is whether EGGL cross-links are quantitatively important in the aging ECM. 
